There you go... the reason for the Ryoncil BLA Resubmission delay
They were waiting for this - I feel better now
I'll see you guys at the AGM - I'll be in a blue top, so come over and say hi if you are in the room!
Key Points:
• Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3trial MSB-GVHD001
• Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recentlypublished studies of children or adults with SR-aGVHD who received best available therapy(BAT) or the only approved agent in adults1-4
• These results reaffirm the potential significance of remestemcel-L as a life-saving therapy forchildren with SR-aGVHD
• These long-term survival outcomes are a key component of the Biologics License Application(BLA) resubmission to the United States Food and Drug Administration (FDA)
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-5
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |